Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease

US9827244B2 · kind B2 · utility

Assignees

• F. Hoffmann-La Roche AG · CH
• Savira pharmaceuticals GmbH · AT
• European Molecular Biology Laboratory · DE

Inventors

• Tanja Schulz-Gasch · Ziefen, CH
• Robert James Weikert · Clifton, US
• Werner Neidhart · Hagenthal-le-Bas, FR
• Helmut Buschmann · Walheim, DE
• Oliver Szolar · Wien, AT
• Andrea Wolkerstorfer · Wien, AT
• Norbert Handler · Wien, AT
• Franz-Ferdinand Roch · Wien, AT
• Stephen Cusack · Seyssinet-Pariset, FR

Key dates

• Filing date: Jun 1, 2016
• Grant date: Nov 28, 2017
• Expiry date: Jun 1, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof,which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.